Physician

Alex S Metzger, M.D.

According to 2025 Medicare claims, Alex Metzger, M.D. (NPI: 1821070590) practices hematology/oncology in the San Rafael, CA market, with the plurality of this provider's patient population coming from Marin, CA. This provider's primary affiliated billing organization is MARIN CANCER CARE, INC. (NPI: 1629370499; TIN: 272191391) and primary practice location at 94904-2018.

Metzger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 481 traditional Medicare patients, billed 138,408 HCPCS/CPT codes, and received $2,184,230 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,361 prescription claims across 184 beneficiaries totaling $3,513,318 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 50 claims. Open Payments data shows 2 records totaling $57. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $949,800 to $2,184,230. Similarly, Part D prescription costs have moved sharply higher in recent years, from $745,902 to $3,513,318. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	395	76,362	$949,800
2016	423	64,899	$918,989
2017	397	77,245	$937,937
2018	380	79,258	$1,124,495
2019	372	82,836	$1,702,766
2020	373	131,741	$2,327,544
2021	424	183,215	$2,402,446
2022	416	151,901	$2,345,867
2023	393	127,275	$2,180,395
2024	481	138,408	$2,184,230

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	91	614	$745,902
2016	95	573	$1,272,234
2017	111	737	$1,374,724
2018	130	697	$1,815,865
2019	127	834	$2,118,898
2020	124	986	$2,314,668
2021	144	1,219	$3,920,008
2022	160	1,523	$3,813,549
2023	164	1,531	$4,009,491
2024	184	1,361	$3,513,318

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	36	$3,668
2016	N/R	N/R	N/R
2017	N/R	26	$408
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	56	$4,020
2021	N/R	24	$2,268
2022	N/R	11	$209
2023	N/R	50	$6,658
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	174	453	$152
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	67	522	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	316	576	$101
96402	Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	69	223	$31
J7030	Infusion, normal saline solution , 1000 cc	62	532	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	50	1,500	$574,672
Abiraterone Acetate	Abiraterone Acetate	226	7,080	$386,556
Revlimid	Lenalidomide	18	490	$347,336
Erleada	Apalutamide	22	690	$314,109
Nubeqa	Darolutamide	23	690	$254,932

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$57	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alex S. Metzger, M.D.?

Tedicare shows public-source Medicare data for Alex S. Metzger, M.D. (NPI 1821070590), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alex S. Metzger, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alex S. Metzger, M.D.?

Alex S. Metzger, M.D. is linked to MARIN CANCER CARE, INC. (billing NPI 1629370499) in the available physician profile data.

Does Alex S. Metzger, M.D. have Open Payments data?

Alex S. Metzger, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.